




1/21






FIG 4






FIG 5


3/21



4/21



5/21





7/21

10/522525

Fig11






Fig12



8/21

Fig. 13



9/21





Fig. 14

10/21



11/21




Fig. 16

12/21




Fig. 17 BEST AVAILABLE COPY

13/21




Fig. 18

BEST AVAILABLE COPY

14 / 21




Fig. 19

BEST AVAILABLE COPY

15/21




Fig. 20

BEST AVAILABLE COPY

16/21




Fig. 21

BEST AVAILABLE COPY

17/21

Formulation Studies with 1.0% PD Solution




FIG 22A

BEST AVAILABLE COPY

18/21

10/522525




FIG 228

BEST AVAILABLE COPY

19/21




FIG 23A

20/21




FIG 23B

BEST AVAILABLE COPY

21/21




FIG 23C